# Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)

> **NCT04069065** · PHASE4 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 146 (estimated)

## Conditions studied

- Liver Transplant

## Interventions

- **DRUG:** Conversion to Once-daily Tacrolimus

## Key facts

- **NCT ID:** NCT04069065
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-31
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-04-08
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069065, "Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04069065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*